Abstracts Archive - Page 28 of 2607 - ACR Meeting Abstracts

Abstract Number: 0125 • ACR Convergence 2025
The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Dionysis Nikolopoulos¹, Konstantinos Charitidis², Julius Lindblom², Maria O Borghi³, Guillermo Barturen⁴, Marta Alarcon-Riquelme⁵, Lorenzo Beretta⁶ and Ioannis Parodis⁷, ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³IRCCS, Istituto Auxologico Italiano, Milan, Italy, ⁴Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁷Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A…
Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Nene Ukonu¹, David Felson², Michael LaValley³ and S. Reza Jafarzadeh⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 0044 • ACR Convergence 2025
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
Abstract Number: 0097 • ACR Convergence 2025
Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction
Yosuke Ono¹, Camilla R.L. Machado², Eunice Choi¹, Wei Wang¹, David Boyle¹ and Gary Firestein², ¹University of California, San Diego, San Diego, ²University of California, San Diego, San Diego, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) play a central role in cartilage destruction and cytokine production in rheumatoid arthritis (RA). Neddylation, a post-translational modification involving NEDD8 conjugation,…
Abstract Number: 0069 • ACR Convergence 2025
Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions
Camilla R.L. Machado¹, Mina Yao¹, David Boyle², Robert J. Benschop³, James T. Parker³, Wei Wang² and Gary Firestein¹, ¹University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, ³Eli Lilly, San Diego
Background/Purpose: RA synovium displays cellular heterogeneity, with gene expression driving disease pathogenesis. Unbiased cell-specific transcriptomes in RA synovium have previously relied primarily on disaggregated tissues…
Abstract Number: 0056 • ACR Convergence 2025
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Maripat Corr¹, Grace Hsueh², Aaron place², David Lucas² and NANCY LANE³, ¹ucsd, San Diego, CA, ²ANI Pharmaceuticals, Inc., Baudette, MN, ³University of California at Davis, School of Medicine, Sacramento, CA
Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Beatriz Vellón-García¹, Gema Dolores García-Delgado², Adrián Llamas Urbano³, Yas Hanaee³, Pedro Ortiz Buitrago⁴, Christian Merlo⁵, Maria del carmen abalos-aguilera⁵, julio Manuel Martinez Moreno⁶, Iván Arias de la Rosa⁷, María Dolores López-Montilla⁸, Rafaela Ortega-Castro⁹, Jerusalén Calvo¹⁰, Lourdes Ladehesa¹¹, Clementina López Medina¹², María Ángeles Puche-Larrubia¹³, Nuria Barbarroja¹⁴, Eduardo Collantes estévez¹⁵, Alejandro Escudero-contreras⁵, Chary López pedrera¹⁶, Jose manuel Villalba¹⁷ and Carlos Pérez Sánchez¹⁸, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ³Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁶Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹⁰IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹¹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ¹³Reina Sofia University Hospital, Granada, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁷Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Matthew Bernett¹, Gregory Moore², Katrina Bykova², Viralkumar Davra², Seung Chu², Michael Sheard², Ruschelle Love², Norman Barlow², Engie Salama², Jitendra Kanodia², Panida Lertkiatmongkol², Dipankar Chaudhuri², Kendra Avery², Hanh Nguyen², Rumana Rashid², Ke Liu², Jing Qi², Araz Eivazi², Thuy Truong², Sher Karki², James Ernst², Rena Bahjat² and John Desjarlais², ¹Xencor, Inc., Pasadena, CA, ²Xencor, Inc., Pasadena
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0046 • ACR Convergence 2025
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Thomas Riley¹, Dana DiRenzo¹, Ellen Romich², Michael Levin³, Scott Damrauer³, Michael George¹, Montserrat Anguera¹, Joshua Baker¹ and Nikhil Jiwrajka¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…
Abstract Number: 0075 • ACR Convergence 2025
Impact of CXCL2 and IL-11 from Rheumatoid Arthritis Synovial Fibroblasts on Angiogenesis and Endothelial Cell Network Formation
Elena Neumann¹, Frederik Loetfering², Paula Welbrink³, Corinna Heck³, Daria Kuersammer³, Klaus Frommer¹, Stefan Rehart⁴ and Ulf Müller-Ladner¹, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Hessen, Germany, ²Justus Liebig University Giessen, Campus Kerckhoff, Bad Nauheim, ³Justus-Liebig-Universität Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁴Agaplesion Markus Hospital, Frankfurt, Hessen, Germany
Background/Purpose: In rheumatoid arthritis (RA), hypervascularization contributes to synovial inflammation. RA synovial fibroblasts (RASF) contribute to cartilage and bone erosion but also promote angiogenesis. Activated…
Abstract Number: 0107 • ACR Convergence 2025
Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
IRENE MARTIN MARTIN¹, CARMEN SAN JOSE MENDEZ², SONIA JIMENEZ BARRIOS³, ELENA MARTIN FERNANDEZ⁴, JULIA MIRANDA MANZANO⁵, DIEGO DIOS SANTOS⁶, JORGE GONZALEZ MARTIN⁷, PABLO ZURITA PRADA⁷, MONICA VAZQUEZ DIAZ⁸ and CARLOS GUILLEN-ASTETE⁹, ¹HOSPITAL VIRGEN DE LAS NIEVES, GRANADA, ²Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴HOSPITAL UNIVERSITARIO RAMON Y CAJAL, MADRID, ⁵FACULTAD BIOMEDICINA, MADRID, ⁶HOSPITAL DE VERÍN, OURENSE, ⁷HOSPITAL UNIVERSITARIO HM SANCHINARRO, MADRID, ⁸HOSPITAL UNIVERSITARIO HLA MONCLOA, MADRID, ⁹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: Elastography (EL) is an imaging technique that evaluates the biomechanical properties of tissues. Pathological tissues have different elastic properties compared to healthy tissues.In diseases…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].